Focus On Zavegepant: The First Intranasal Third-Generation Gepant

References

• Leonardi M , GrazziL , D’amicoDet al. Global burden of headache disorders in children and adolescents 2007�2017. Int. J. Environ. Res. Public Health18(1), 250 (2021).
   Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd Edition. Cephalalgia38(1), 1�211 (2018).
   PubMed Web of Science ®Google Scholar
• Bigal ME , LibermanJN , LiptonRB. Age-dependent prevalence and clinical features of migraine. Neurology67(2), 246�251 (2006).
   PubMed Web of Science ®Google Scholar
• Hepp Z , DodickDW , VaronSFet al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia37(5), 470�485 (2017).
   PubMed Web of Science ®Google Scholar
• Silberstein SD , HollandS , FreitagF , DodickDW , ArgoffC , AshmanE. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology78(17), 1337�1345 (2012).
   PubMed Web of Science ®Google Scholar
• Scuteri D , AdornettoA , Rombol�Let al. New trends in migraine pharmacology: targeting calcitonin gene-related peptide (CGRP) with monoclonal antibodies. Front. Pharmacol.10, 363 (2019).
   PubMed Web of Science ®Google Scholar
• Scuteri D , AdornettoA , Rombol�Let al. Pattern of triptans use: a retrospective prescription study in Calabria, Italy. Neural Regen. Res.15(7), 1340�1343 (2020).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ , EdvinssonL , EkmanR. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol.28(2), 183�187 (1990).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ , EdvinssonL. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol.33(1), 48�56 (1993).
   PubMed Web of Science ®Google Scholar
• Van Dongen RM , ZielmanR , NogaMet al. Migraine biomarkers in cerebrospinal fluid: a systematic review and meta-analysis. Cephalalgia37(1), 49�63 (2017).
   PubMed Web of Science ®Google Scholar
• Xanthos DN , Sandk�hlerJ. Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity. Nat. Rev. Neurosci.15(1), 43�53 (2014).
   PubMed Web of Science ®Google Scholar
• Deen M , CorrentiE , KammKet al. Blocking CGRP in migraine patients � a review of pros and cons. J. Headache Pain18(1), 96 (2017).
   PubMed Web of Science ®Google Scholar
• Eftekhari S , SalvatoreCA , CalamariA , KaneSA , TajtiJ , EdvinssonL. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience169(2), 683�696 (2010).
   PubMed Web of Science ®Google Scholar
• Rosenfeld MG , MermodJJ , AmaraSGet al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature304(5922), 129�135 (1983).
   PubMed Web of Science ®Google Scholar
• Maleki N , SzaboE , BecerraLet al. Ictal and interictal brain activation in episodic migraine: neural basis for extent of allodynia. PlOS ONE16(1), e0244320 (2021).
   PubMed Web of Science ®Google Scholar
• Burstein R , CutrerMF , YarnitskyD. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain123 (Pt 8), 1703�1709 (2000).
   PubMed Web of Science ®Google Scholar
• Lassen L , HaderslevP , JacobsenV , IversenH , SperlingB , OlesenJ. CGRP may play a causative role in migraine. Cephalalgia22(1), 54�61 (2002).
   PubMed Web of Science ®Google Scholar
• Scuteri D , CorasanitiMT , ToninP , NicoteraP , BagettaG. Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy. J. Headache Pain22(1), 87 (2021).
   PubMed Web of Science ®Google Scholar
• Scuteri D , Rombol�L , ToninPet al. Genetic variants of CGRP signaling pathway in migraine: impact on novel therapeutics. Confinia Cephalalgica31(3), e2021023, 1�11 (2021).
   Google Scholar
• Goadsby PJ , HollandPR , Martins-OliveiraM , HoffmannJ , SchankinC , AkermanS. Pathophysiology of migraine: a disorder of sensory processing. Physiol. Rev.97(2), 553�622 (2017).
   PubMed Web of Science ®Google Scholar
• Cameron C , KellyS , HsiehSCet al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache55 (Suppl. 4), 221�235 (2015).
   PubMed Web of Science ®Google Scholar
• Scuteri D , ToninP , NicoteraP , BagettaG , CorasanitiMT. Real-world considerations for newly approved CGRP receptor antagonists in migraine care. Expert Rev. Neurother.22(3), 221�230 (2022).
   PubMed Web of Science ®Google Scholar
• Olesen J , DienerHC , HusstedtIWet al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. New Engl. J. Med.350(11), 1104�1110 (2004).
   PubMed Web of Science ®Google Scholar
• Hewitt DJ , AuroraSK , DodickDWet al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia31(6), 712�722 (2011).
   PubMed Web of Science ®Google Scholar
• Tepper SJ , ClevesC. Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine. Curr. Opin. Investig. Drugs10(7), 711�720 (2009).
   PubMedGoogle Scholar
• Ho TW , FerrariMD , DodickDWet al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet372(9656), 2115�2123 (2008).
   PubMed Web of Science ®Google Scholar
• Martelletti P , EdvinssonL , AshinaM. Shaping the future of migraine targeting calcitonin-gene-related-peptide with the disease-modifying migraine drugs (DMMDs). J. Headache Pain20(1), 60 (2019).
   PubMed Web of Science ®Google Scholar
• Croop R , GoadsbyPJ , StockDAet al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet394(10200), 737�745 (2019).
   PubMed Web of Science ®Google Scholar
• Dodick DW , LiptonRB , AilaniJet al. Ubrogepant for the treatment of migraine. New Engl. J. Med.381(23), 2230�2241 (2019).
   PubMed Web of Science ®Google Scholar
• Lipton RB , DodickDW , AilaniJet al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: The ACHIEVE II Randomized Clinical Trial. JAMA322(19), 1887�1898 (2019).
   PubMed Web of Science ®Google Scholar
• Lipton RB , CroopR , StockEGet al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. New Engl. J. Med.381(2), 142�149 (2019).
   PubMed Web of Science ®Google Scholar
• Ailani J , LiptonRB , GoadsbyPJet al. Atogepant for the preventive treatment of migraine. New Engl. J. Med.385(8), 695�706 (2021).
   PubMed Web of Science ®Google Scholar
• Lipton RB , Pozo-RosichP , BlumenfeldAMet al. Rates of response to atogepant for migraine prophylaxis among adults: a secondary analysis of a randomized clinical trial. JAMA Netw. Open5(6), e2215499 (2022).
   PubMed Web of Science ®Google Scholar
• Moreno-Ajona D , P�rez-Rodr�guezA , GoadsbyPJ. Small-molecule CGRP receptor antagonists: a new approach to the acute and preventive treatment of migraine. Med. Drug Discov.7, 100053 (2020).
   Google Scholar
• Dubowchik GM , ConwayCM , XinAW. Blocking the CGRP pathway for acute and preventive treatment of migraine: the evolution of success. J. Med. Chem.63(13), 6600�6623 (2020).
   PubMed Web of Science ®Google Scholar
• Chaturvedula PV , MercerSE , PinSSet al. Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery. Bioorg. Med. Chem. Lett.23(11), 3157�3161 (2013).
   PubMed Web of Science ®Google Scholar
• Mercer SE , ChaturvedulaPV , ConwayCMet al. Azepino-indazoles as calcitonin gene-related peptide (CGRP) receptor antagonists. Bioorg. Med. Chem. Lett.31, 127624 (2021).
   PubMed Web of Science ®Google Scholar
• Dos Santos JBR , DaSilva MRR. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: a review. Eur. J. Pharmacol.922, 174902 (2022).
   PubMed Web of Science ®Google Scholar
• Woodhead JL , SilerSQ , HowellBA , WatkinsPB , ConwayC. Comparing the liver safety profiles of 4 next-generation CGRP receptor antagonists to the hepatotoxic CGRP inhibitor telcagepant using quantitative systems toxicology modeling. Toxicol. Sci. doi:10.1093/toxsci/kfac051 (2022).
   PubMed Web of Science ®Google Scholar
• Woodhead JL , BrockWJ , RothSEet al. Application of a mechanistic model to evaluate putative mechanisms of tolvaptan drug-induced liver injury and identify patient susceptibility factors. Toxicol. Sci.155(1), 61�74 (2017).
   PubMed Web of Science ®Google Scholar
• Longo DM , WoodheadJL , WalkerPet al. Quantitative systems toxicology analysis of in vitro mechanistic assays reveals importance of bile acid accumulation and mitochondrial dysfunction in TAK-875-induced liver injury. Toxicol. Sci.167(2), 458�467 (2019).
   PubMed Web of Science ®Google Scholar
• Cipolla F , CapiM , LionettoL , DeBernardini D , DeAngelis V , MartellettiP. Zavegepant. Calcitonin gene-related peptide (CGRP) receptor antagonist, treatment of migraine. Drugs Future46(4), 281 (2021).
   Web of Science ®Google Scholar
• Martelletti P . An unexpected and suspended time. J. Headache Pain21(1), 36 (2020).
   PubMed Web of Science ®Google Scholar
• �tekl�c M , ZajacekD , Bucinsk�L. 3CL(pro) and PL(pro) affinity, a docking study to fight COVID19 based on 900 compounds from PubChem and literature. Are there new drugs to be found?J. Mol. Struct.1245, 130968 (2021).
   PubMed Web of Science ®Google Scholar
• Cipolla F , CapiM , LionettoL , DeBernardini D , DeAngelis V , MartellettiP. Zavegepant. Calcitonin gene-related peptide (CGRP) receptor antagonist, treatment of migraine. Drugs Future46(4), 1�8 ( Advanced Publication) (2021).
   Web of Science ®Google Scholar
• www.Prnewswire.Com/News-Releases/Biohaven-Reports-Positive-Topline-Results-from-Pivotal-Migraine-Trial-of-Intranasal-Zavegepant-Demonstrating-Ultra-Rapid-Pain-Relief-by-15-Minutes-Prepares-for-Submission-of-New-Drug-Application-301437767.html
   Google Scholar
• Altamura C , BrunelliN , MarcosanoM , FofiL , VernieriF. Gepants�a long way to cure: a narrative review. Neurol. Sci. doi:10.1007/s10072-022-06184-8 (2022).
   Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT04804033
   Google Scholar
• www.prnewswire.com/news-releases/biohaven-achieves-positive-topline-results-in-pivotal-phase-23-study-of-vazegepant-the-first-and-only-intranasal-cgrp-receptor-antagonist-in-clinical-development-for-the-acute-treatment-of-migraine-300976000.html
   Google Scholar
• Moreno-Ajona D , P�rez-Rodr�guezA , GoadsbyPJ. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?Curr. Opin. Neurol.33(3), 309�315 (2020).
   PubMed Web of Science ®Google Scholar
• Bayer A , TaddW. Unjustified exclusion of elderly people from studies submitted to research ethics committee for approval: descriptive study. BMJ321(7267), 992�993 (2000).
   PubMedGoogle Scholar
• Herrero S , GuerreroAL , RuizMet al. Migraine in the elderly: clinical characteristics in a series of 71 cases. J. Headache Pain14(1), P152 (2013).
   Google Scholar
• Scuteri D , MantovaniE , TamburinSet al. Opioids in post-stroke pain: a systematic review and meta-analysis. Front. pharmacol.11, 587050 (2020).
   PubMedGoogle Scholar
• Scuteri D , ContradaM , LoriaTet al. Pain and agitation treatment in severe dementia patients: The need for Italian Mobilization-Observation-Behavior-Intensity-Dementia (I-MOBID2) pain scale translation, adaptation and validation with psychometric testing. Biomed. Pharmacother.150, 113013 (2022).
   PubMed Web of Science ®Google Scholar
• Scuteri D , VulneraM , PiroBet al. Pattern of treatment of behavioural and psychological symptoms of dementia and pain: evidence on pharmacoutilization from a large real-world sample and from a centre for cognitive disturbances and dementia. Eur. J. Clin. Pharmacol.77(2), 241�249 (2021).
   PubMed Web of Science ®Google Scholar
• Scuteri D , BerliocchiL , Rombol�Let al. Effects of aging on formalin-induced pain behavior and analgesic activity of gabapentin in C57BL/6 Mice. Front. Pharmacol.11, 663 (2020).
   PubMed Web of Science ®Google Scholar
• Scuteri D , CorasanitiMT , ToninP , BagettaG. Eptinezumab for the treatment of migraine. Drugs Today55(11), 695�703 (2019).
   PubMed Web of Science ®Google Scholar
• Winner PK , McallisterP , ChakhavaGet al. Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial. JAMA325(23), 2348�2356 (2021).
   PubMed Web of Science ®Google Scholar
• Scuteri D , BagettaG. Progress in the treatment of migraine attacks: from traditional approaches to eptinezumab. Pharmaceuticals (Basel)14(9), (2021).
   PubMedGoogle Scholar
• Rapoport AM , LiptonRB. Potassium channel openers�novel triggers of aura and migraine. Nat. Rev. Neurol.17(7), 397�398 (2021).
   PubMed Web of Science ®Google Scholar
• Parlar A , ArslanSO , �amSA. Glabridin alleviates inflammation and nociception in rodents by activating BK(Ca) channels and reducing NO levels. Biol. Pharm. Bull.43(5), 884�897 (2020).
   PubMed Web of Science ®Google Scholar
• Scuteri D , CassanoR , TrombinoSet al. Development and translation of NanoBEO, a nanotechnology-based delivery system of bergamot essential oil deprived of furocumarins, in the control of agitation in severe dementia. Pharmaceutics13(3), (2021).
   PubMed Web of Science ®Google Scholar
• Scuteri D , SandriniG , TamburinSet al. Bergamot rehabilitation AgaINst agitation in dementia (BRAINAID): study protocol for a randomized, double-blind, placebo-controlled trial to assess the efficacy of furocoumarin-free bergamot loaded in a nanotechnology-based delivery system of the essential oil in the treatment of agitation in elderly affected by severe dementia. Phytother. Res.35(10), 5333�5338 (2021).
   PubMed Web of Science ®Google Scholar
• Rombol� L , ScuteriD , WatanabeCet al. Role of 5-HT1A receptor in the anxiolytic-relaxant effects of bergamot essential oil in rodent. Int. J. Mol. Sci.21(7), (2020).
   Web of Science ®Google Scholar
• Scuteri D , Rombol�L , CrudoMet al. Preclinical characterization of antinociceptive effect of bergamot essential oil and of its fractions for rational translation in complementary therapy. Pharmaceutics14(2), (2022).
   Web of Science ®Google Scholar
• Scuteri D , Rombol�L , CrudoMet al. Translational value of the transdermal administration of bergamot essential oil and of its fractions. Pharmaceutics14(5), (2022).
   Web of Science ®Google Scholar
• Rombol� L , ScuteriD , MarilisaSet al. Pharmacokinetic interactions between herbal medicines and drugs: their mechanisms and clinical relevance. Life (Basel)10(7), (2020).
   Web of Science ®Google Scholar